X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PAS-004 is is a small molecule allosteric inhibitor of MEK 1/2. It is being evaluated for the treatment of neurofibromatosis type 1 and other cancer indications.
Lead Product(s): PAS-004
Therapeutic Area: Oncology Product Name: PAS-004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
PAS-004 is is a small molecule allosteric inhibitor of MEK 1/2. It is being evaluated for the treatment of neurofibromatosis type 1 and other cancer indications.
Lead Product(s): PAS-004
Therapeutic Area: Oncology Product Name: PAS-004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
PAS-004 (CIP-137401) is a macrocyclic MEK 1/2 inhibitor. Currently it is being evaluated for the treatment of patients with MAPK pathway driven advanced solid tumors with a documented RAS, RAF or NF1 mutation or patients who have failed BRAF/MEK inhibition.
Lead Product(s): CIP-137401
Therapeutic Area: Oncology Product Name: PAS-004
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. It showed positive In vivo preclinical efficacy in NRAS mutation cancer xenograft models.
Lead Product(s): CIP-137401
Therapeutic Area: Genetic Disease Product Name: PAS-004
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
PAS-004 is a first macrocyclic MEK 1/2 Inhibitor small molecule drug which is being investigated for the treatent of RAS, RAF or NF1 mutated solid tumors.
Lead Product(s): PAS-004
Therapeutic Area: Oncology Product Name: PAS-004
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
PAS-003 is a fully humanized proprietary monoclonal antibody targeting α5β1 integrin for the treatment of both sporadic and familial amyotrophic lateral sclerosis (ALS) and other neurological diseases.
Lead Product(s): PAS-003
Therapeutic Area: Neurology Product Name: PAS-003
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
PAS-002 is a proprietary engineered DNA plasmid vaccine to tolerize the immune system to GlialCAM which is found in brain’s white matter. GlialCAM shares a component of its structure that mimics an identical component of EBNA-1, playing a critical role in triggering MS.
Lead Product(s): PAS-002
Therapeutic Area: Neurology Product Name: PAS-002
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and motility.
Lead Product(s): CIP-137401
Therapeutic Area: Genetic Disease Product Name: PAS-004
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: WuXi AppTec Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 18, 2023
Details:
PAS-003 is a monoclonal antibody targeting alpha5/beta1 integrin for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases. The target, Alpha 5 Beta 1 integrin, and its potential role in ALS is supported by post-mortem human tissue studies.
Lead Product(s): PAS-003
Therapeutic Area: Neurology Product Name: PAS-003
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
PAS002 is an engineered DNA plasmid designed to tolerize the immune system to GlialCAM,effectively reduces disease severity, delays onset of illness, while also reducing relapse severity.
Lead Product(s): PAS002
Therapeutic Area: Neurology Product Name: PAS002
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
